Heather Bresch, chief executive officer of Mylan Inc., speaks during a Bloomberg Television interview in New York, U.S., on Thursday, May 1, 2014. Bresch discussed the U.S. corporate tax code and the impact of consolidation in the pharmaceutical industry on generic drugmakers like Mylan. Photographer: Chris Goodney/Bloomberg via Getty ImagesBloomberg via Getty Images
- Previous Rank
Bresch, the first female CEO of Mylan, announced in July her plan to purchase Abbott's generic-drug business for $5.3 billion. If it happens, Mylan may redomicile in Europe for tax purposes. Bresch is unfazed by external criticism of the possible move.